Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
Crucell Receives NIH Award for the Development of Influenza Monoclonal Antibodies
New awards of $300 million for Quinvaxem(R) bringing total value up to $800 million
Crucell Announces Second Quarter 2009 Results
StockPreacher.com Issues Trading Outlook for Novavax Inc.
MVI and Crucell Announce Collaboration new Malaria Vaccine Approach
Crucell Announces Positive Results of Phase II Rabies Monoclonal Antibody Combination Clinical Study in Philippines
Xcellerex Announces Sale of FlexFactory™ Bioproduction Line to Crucell for Vaccine, Monoclonal Antibody Manufacturing Facility
Crucell 2009 Annual General Meeting of Shareholders 2008 Financial Statements Adopted; All Resolutions Approved
Crucell to Release First Quarter 2009 Results on Wednesday, May 6, 2009
Reportlinker Adds World Pharmaceutical Contract Manufacturing Market Report
DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
Crucell Announces Profits for Full Year 2008
BenchmarkJournal.Com (Complimentary) Analyst Review for ATVI, ERTS, THQI and CRXL
Crucell Announces STAR(R) Research and Commercial License Agreement with Centocor, Inc.
DSM Biologics and Crucell Announce PER.C6(R) License Agreement with CSL Ltd.
DSM and Crucell Announce PER.C6(R) Research License Agreement with GSK
DSM Biologics and Crucell Announce PER.C6(R) Research License Agreement with GlaxoSmithKline
Crucell Announces Excellent Results for Influenza Antibody
DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell Line Proteins
Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
